Company Overview
TAKE LIMITED, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services. It also provides embed digital and employ mobile solutions for patient centricity insight in life science sector; and payer solutions, including access to billing insight through cloud adoption. In addition, the company offers payer-provider digital solution, which includes personalized medicine, wellness, and patient engagement; and medical device solution, such as technological transformation with chip level programming, DICOM devices, wearables, PROM, nano devices, and miOTs. The company was formerly known as TAKE Solutions Limited and change its name to TAKE LIMITED in June 2026. TAKE LIMITED was incorporated in 2000 and is based in Chennai, India.
Why Investors Should Care
Generates a return on equity of 35.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 15.4%.
Net profit has compounded at 36.9% per year over the last five years.
Trades at a P/E of 34.5, below the sector median of 40.0.
Maintains a net profit margin of 15.2%.
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -71.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.1%, profit CAGR 36.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.07% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 36.94% |
| 1 Year: | -71.04% |
Stock Price Performance
| 1 Year: | +58.06% |
| 6 Months: | -57.82% |
| 3 Months: | -50.93% |
| 1 Month: | -36.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.84 · Oversold
P/E of 34.55 is below the sector median of 40.02 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 35.0%.
- Profit CAGR of 36.9% over 5 years.
CONS
- Revenue declined at -34.1% CAGR over 5 years.
- Trading 71.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TAKE TAKE LIMITED NSEPHARMA | 14.51 | 34.55 | ₹212.17 Cr | 0.00% | 15.37% | 35.00% | -34.07% | 36.94% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 54.19 Cr |
| Cost of Revenue | 0 | 0 | 0 | 0 | 54.20 Cr |
| Gross Profit | 0 | 0 | 0 | 0 | -1.42 L |
| Operating Expenses | 2.90 Cr | 1.15 Cr | 77.60 L | 35.13 L | 81.06 L |
| Operating Income | -2.90 Cr | -1.15 Cr | -77.60 L | -35.13 L | -82.48 L |
| EBITDA | 5.63 Cr | 55.80 L | -73.30 L | 1.11 Cr | 4.36 Cr |
| Interest Expense | 72.60 L | 24.40 L | 17.50 L | 9,000 | 0 |
| Pretax Income | 4.89 Cr | 30.40 L | -91.00 L | 1.11 Cr | 4.36 Cr |
| Tax Provision | 0 | 0 | 0 | 0 | 0 |
| Net Income | 47.68 Cr | -4.88 Cr | -91.00 L | 1.11 Cr | 4.36 Cr |
| Diluted EPS | 3.26 | -0.33 | -0.06 | 0.07 | 0.29 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 189.07 Cr | 3.60 Cr | 0 | 54.19 Cr |
| Cost of Revenue | - | 83.01 Cr | 3.15 Cr | 0 | 54.20 Cr |
| Gross Profit | - | 106.06 Cr | 45.30 L | 0 | -1.42 L |
| Operating Expenses | - | 100.24 Cr | 6.97 Cr | 7.52 Cr | 1.91 Cr |
| Operating Income | - | 5.82 Cr | -6.52 Cr | -7.52 Cr | -1.92 Cr |
| EBITDA | - | -21.34 Cr | -52.22 Cr | 2.74 Cr | 4.77 Cr |
| Interest Expense | - | 7.10 Cr | 2.27 Cr | 1.96 Cr | 34.89 L |
| Pretax Income | - | -45.27 Cr | -62.37 Cr | 73.80 L | 4.42 Cr |
| Tax Provision | - | 1.68 Cr | 4.01 Cr | 0 | 16.00 L |
| Net Income | - | -100.27 Cr | -119.62 Cr | 37.47 Cr | 10.85 Cr |
| Diluted EPS | - | -6.86 | -8.18 | 2.53 | 0.74 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 224.38 Cr | 88.11 Cr | 36.48 Cr | 36.24 Cr |
| Current Assets | - | 90.19 Cr | 35.28 Cr | 23.55 Cr | 23.77 Cr |
| Cash & Equivalents | - | 10.72 Cr | 84.50 L | 3.37 Cr | 25.96 L |
| Inventory | - | 77.60 L | 79.60 L | 0 | 0 |
| Receivables | - | 30.04 Cr | 7.04 Cr | 0 | 21.81 L |
| Total Liabilities | - | 115.78 Cr | 96.98 Cr | 15.95 Cr | 5.24 Cr |
| Current Liabilities | - | 100.90 Cr | 89.16 Cr | 15.95 Cr | 5.24 Cr |
| Long Term Debt | - | 5.76 Cr | 75.00 L | 0 | 0 |
| Total Debt | - | 46.37 Cr | 37.09 Cr | 0 | 0 |
| Total Equity | - | 108.60 Cr | -8.87 Cr | 20.53 Cr | 31.00 Cr |
| Shares Outstanding | - | 14.79 Cr | 14.79 Cr | 14.79 Cr | 14.79 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 20.02 Cr | 9.32 Cr | -16.37 Cr | -4.13 Cr |
| Investing Cash Flow | - | -2.12 Cr | -7.46 Cr | 22.21 Cr | 1.74 Cr |
| Financing Cash Flow | - | -35.72 Cr | -11.73 Cr | -3.24 Cr | -72.36 L |
| Capital Expenditure | -31.21 Cr | -32.40 Cr | -7.92 Cr | - | - |
| Free Cash Flow | - | -12.38 Cr | 1.40 Cr | -16.37 Cr | -4.13 Cr |
| Net Change in Cash | - | -17.83 Cr | -9.88 Cr | 2.60 Cr | -3.11 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 56.1% | 12.6% | - | -0.0% |
| Operating Margin % | - | 3.1% | -181.0% | - | -3.5% |
| Net Margin % | - | -53.0% | -3,320.9% | - | 20.0% |
| ROE % | - | -92.3% | 1,348.1% | 182.5% | 35.0% |
| ROCE % | - | 4.7% | 619.9% | -36.6% | -6.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TAKE
Great New York State Fair closes Monday as vendors take stock amid higher costs - WSTM
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQb1RpYzJlQ1N1cUtJOFViRHZkSW5CV000VFpCdXdIcC1VMVJSTEdPNGMwQ0dHSVp5cDhvcl9pQUkyLUpWQUJtMzFBM0lwdVRqQUpiYW8wMmpDOW5wSUhNdkZ3VGJtaHJnUms4XzhvdzZqX2x0U0twVG9fdmZtSnJNNVhMcWllSElzcFRnSS…
Store Openings and Closures Slow in 2026 as Retailers Take Stock - Retail TouchPoints
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxONnNDeVVXN0VXaUVwRjBOQUtvVVVpQkVjNG91Q01UOEVxcDhVQnlKcEROOWFnUk5KbmxMQUhrUk1VU1N1LV9rbndFTTRmd2hMM3pkTEFDdlpHRngzYzNGTFAwdFlyUGFSZ01hOHFaNzBneXM1cnRrSHZVeUZjN3NTTUN0OFZfemVPa1pkYU…
How To Take Advantage Of This Rising Stock With Reduced Risk - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPMGQ5YVhrOHJVQTZfekZDT3c4Njk1akI3RjJjWlktSWlkVXdPTXQ5RDd5N3MwNm50aEt4b2o5LU5zUTM3dl9XWVR2d3NOWk5xZ0Fxam1wQVZpVHd2andJN05kVkVFd09kNFZHYThkZXAwdkNobklmN0FyS3RyTWlrUzJDVHRzamg4Q3hjMF…
Salesforce stock falls as investors appear to take profits amid a broader rate-driven software selloff - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQRG9HY3I1dUhBNWdxemFuOWhoSXNaTUg5cVRoV0k2LXZHSks5Umh6aktWTHgya0ZqZVdYRDVJRTA1R1d3aXpVSGtYMUUyMDZsWjV4Z3YxaUxCNFF2Z0ZDNG42SHpNb3hGdXVYQzl6RThXYWdTWk9wcmgyeHJHcW5VeFJsblU1eC1TQ190Y0…
Take-Two CFO Sells 1,335 Company Shares as Grand Theft Auto 6 Nears Launch - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOekdVVFhmckV2LXhXZlEtSXRfcWJQU1pUYkkwS0xHQU42N0NvaENTU204WEN3Y01Zb2JURUhBeHFHd3RmY0F6TGtKTzlsRlhnbWE4YTBERTR4SmttRFI3Q3pKSnZzZGNhLTZtcHg3M1VoTFRvMzJOdFJHMTdZZjYyZ05YSkZ1OEVzb2ZBNE…
Take Stock in Children angel mentor changes lives in Escambia County - WEAR-TV
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQX0c3ejdYV0NVbVVqN2xGY2pUay15V2hPMFRlcW51QlFaQ3BNUWlzb2RZZUZQV29XeFpUdUlFNFdfUldEcTBzUWFVbi0tRFFIY0J5WXkzOFZrRTJFMmZjTVF1YmlPcDhEeVlUOHBXUzJMUUZVbFRzel9PR0JGUzdWRDNpYk1yNElHNzIxV2…
TAKE — Frequently Asked Questions
What is the current share price of TAKE LIMITED (TAKE)?
As of 2026-09-20 09:43 IST, TAKE LIMITED (TAKE) trades at ₹14.51 on NSE. Its 52-week range is ₹9.18 to ₹50.14.
What is the market capitalisation of TAKE?
TAKE LIMITED (TAKE) has a market capitalisation of ₹212.17 Cr on NSE.
What is the P/E ratio of TAKE?
TAKE trades at a trailing price-to-earnings (P/E) ratio of 34.55. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 7.75.
What is the return on equity (ROE) of TAKE?
TAKE has a return on equity (ROE) of 35.00%. Its return on capital employed (ROCE) is 15.37%.
Is TAKE a good stock to buy?
This page provides a data-driven analysis of TAKE LIMITED (TAKE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.